generic wellbutrin

Shares of Hayward based Impax Laboratories generic wellbutrin inc. , which also wants to market a generic version of Wellbutrin, fell $1. 15, or 7. 3 percent, to Generic wellbutrin $14. 51 in generic wellbutrin monday's trading. District court in southern Florida decided to hear Andrx's generic wellbutrin case against Eon Labs concerning Eon's recent announcement to launch bupropion hydrochloride, the generic equivalent of GlaxoSmithKline's Wellbutrin SR. Food and Drug Administration ("FDA") and Canadian Therapeutic Products Directorate ("TPD") approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished products, third parties, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission ("SEC") and the Ontario Securities Commission ("OSC"). Distribution of the products will commence generic wellbutrin immediately. Glaxo received FDA approval of this product in June 2002. For more information, please visit the Company's Web site at: www. Impaxlabs. Jeffrey Long-McGie, an analyst with ThinkEquity Partners, called the quarter fantastic and said the company's earnings per share of 14 cents came in 7 cents ahead of his best-case scenario.

Northumbrian Water was not so lucky, Generic wellbutrin falling 1p to 106. 75p, as Merrill generic wellbutrin lynch was heard warning investors that the group's current financial structure was unsustainable and that a rights issue early next year was a real risk. This gives the pharmaceutical giant time to switch patients to its new improved Wellbutrin XL formula.

We have had applications pending for the lower two strengths, generic wellbutrin the 100 and 150 mg, for almost two years now, said Barry Edwards, the company's co-CEO. Sales of over $1. 7 billion for the twelve-month period ended May 31, 2003 according to NDCHealth.
The product is being sold under the Global label and marketed by IMPAX's Global Pharmaceuticals division. The physician prescribing the Zyban didn't have a list of the patient's other medications. Anchen has been granted summary judgment of noninfringement with regard to the Anchen product.
-- IMPAX Laboratories, Inc. Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.